Sharemaestro Newsreel

Eli Lilly and Company Q2 Earnings Call Highlights

Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 …

Why PG, JNJ, and KO Could Surprise Investors Next Year

Quick Read PG and JNJ target $180 and $300 respectively, with JNJ's oncology pipeline posting drug growth up to 83% in Q1. KO's FIFA World Cup 2026 activation across 180+ markets, paired with Zero Sugar volume up 16%, builds the case for $100. It …

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

Key Points Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of …

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] …

Insider trades: Microsoft, Meta, Pfizer among notable names

[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small …

Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was …

Earnings Scoreboard: 86% of S&P 500 reporting firms top EPS estimates as 79% post Y/Y profit growth

[Rolled newspaper with the headline Quarterly Results] Zerbor S&P 500 earnings activity accelerated this week, with more than 130 index members reporting quarterly results that provided key insights into corporate margin health, spending trends, and overall macroeconomic strength. EARNINGS ROUNDUP: * BOTTOM LINE (EPS): …

Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …

Pfizer Inc (PFE) Aktienanalyse & Prognose

Gilead Sciences Inc (GILD) Aktuelle Aktien-News

Ist Johnson & Johnson (JNJ) Nach Starken Darzalex Lizenzgebühren Jetzt Voll Bewertet?

Healthcare giant slashes key consultation fee to beat rivals

CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the …

Bristol-Myers Squibb Co (BMY) Aktienanalyse & Prognose

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Quick Read A blended portfolio made up of two-thirds dividend growth at 3.5% and one-third income at 6% generates $56,000 annually from $1.25M, beating the 4% rule without touching principal. Dividend growers like JNJ and AMGN raising payouts at 6% annually double retirement income …

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …

Johnson & Johnson (JNJ) Aktienanalyse & Prognose

Novo Nordisk A/S (NVO) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * …

Pfizer Inc (PFE) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …

Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half …

Warum die Pfizer-Aktie (PFE) trotz eines Nettoverlusts im zweiten Quartal um 5,2 % gestiegen ist, nachdem das Unternehmen seine Prognose für 2026 angehoben hat

Johnson & Johnson (JNJ) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

**Novo Nordisk hebt Prognose an – warum die Aktie trotzdem fällt**

Sanofi Aktie: 33,3 Prozent EPS-Wachstum im Q2

Pfizer’s Q2 Earnings Beat by Double Digits. A $4.3 Billion Writedown Stole the Headline.

GSK plc (GSK) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Bristol-Myers Squibb Co (BMY) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Gilead Sciences Inc (GILD) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

AWSX der Telegram-Trader.de: Gilead Sciences überzeugt mit starkem Wachstum - Prognose Kerngeschäft steigt

Pfizer Inc. Passt Gewinnprognose für 2026 an